Prostate, doctor prostate cancer study diagnostic classification prostate cancer treatment cannabis

Prostate, doctor prostate cancer study diagnostic classification prostate cancer treatment cannabis marijuana hormone therapy bicalutamide Enzalutamid, Xtandi Zytiga, abiraterone radiotherapy Xofigo, radium Ra 223 chemotherapy hyperthermia immunotherapy, T cells, vaccine Provenge, Sipuleucel T Impotence, Potency urinary incontinence testosterone Testosterone Increase, Buy Klinefelter syndrome , lack of testosterone growth forecast diet psyche fatigue syndrome severe skin diseases disability termination skin diseases due to Cancer News Contact skin diseases Imprint directory books
Prostate cancer growth is promoted in many cases, the male sex hormone testosterone. With drugs can inhibit the production of testosterone, which can become too low hormone levels that the tumor can not spread further (chemical castration). The same objective can be achieved by the removal of the testes reach (surgical castration). skin diseases
Over time, many prostate tumors are insensitive but this forced reduction in testosterone levels, that is: There satisfy them then the extremely low testosterone levels, to continue to grow. Some tumors also provide their own testosterone ago. Physicians speak of castration-resistant skin diseases prostate cancer.
Abiraterone is a so-called testosterone inhibitor (testosterone inhibitor). In contrast to the drugs that are used as part of hormone therapy (LHRH agonist), blocked abiraterone not only the testosterone production in the testes, but also in the epididymis and in the tumor tissue itself, the hormone levels reduced below the detection limit when the preparation co-administered with the LHRH agonist or is combined with a testicle removal.
Zytiga is used only in conjunction with a corticosteroid (prednisone or prednisolone). The reason: Zytiga can cause in the body high blood pressure, potassium deficiency and fluid retention. The concomitant corticosteroid reduce the risk and severity of such side effects.
Abiraterone is the first representative of a new group of active substances that inhibit the enzyme cytochrome P-450c17 (CYP17), skin diseases a key enzyme in the biosynthesis of testosterone. Under this treatment the tumor disease can often be stabilized for years before it finally comes to a renewed increase in the PSA. The overall survival is significantly prolongs. skin diseases
We report on an extension of progression-free survival from 8.3 to 16.5 months. The overall survival has been extended, according to the FDA from 30.1 to 35.3 months. Abiraterone hesitated out also the time to onset of chemotherapy, it lowered the Opiatverbrauch the (suffering skin diseases from painful bone metastases) patients and improved (temporarily) their general condition.
Unfortunately, the response rate is not particularly high (from the U.S. community). Approximately 1/3 speak very well, about 1/3 have a relative short-term slowdown in growth and PSA in the last third of the PSA value is undiminished. It comes in about half the cases, which respond to Zytiga to a PSA flare. This may take up to 12 weeks to fall to the PSA value then begins. The not so good Ergebnise komen concluded therefore, wil in many cases the tumor hormone is already resistant. skin diseases The future shows whether the simultaneous application along with Enzalutamid-Xtandi would be a solution here. Side effects
The most common side effects (they can occur, but need not, because each person differently responsive skin diseases to medication): Very Common: urinary tract infections, potassium deficiency, high blood pressure, fluid retention skin diseases (edema) in the arms and legs Common: Elevated triglyceride levels, heart failure, chest tightness (angina pectoris), cardiac skin diseases arrhythmias (such as atrial fibrillation and rapid heart rate = tachycardia), increased ALT levels Uncommon side effects: adrenal insufficiency abiraterone can damage the liver. Interactions
Food can greatly affect the uptake of Zytiga . Therefore, the medication should not be taken with a meal (see warnings). Caution during concomitant skin diseases use of drugs that are activated or processed by the enzyme CYP2D6 such as metoprolol or propranolol (for cardiovascular disease), desipramine, or venlafaxine (for depression), haloperidol (psychoses), propafenone or Flecanid (in heart rhythm disorders) , codeine (cough suppressants, analgesics), tramadol (pain killer). Drugs that inhibit the enzyme CYP3A4 or stimulate its activity, skin diseases could also influence processing of Zytiga . Such drugs should therefore skin diseases not be taken or used with caution. skin diseases Examples: ketoconazole, and voriconazole skin diseases (for fungal infections), saquinavir, indinavir and ritonavir (medicines for HIV infection), phenytoin, carbamazepine, and phenobarbital (for epilepsy